Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study

Abstract. Background:. Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease. China has the world's largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organiz...

Full description

Bibliographic Details
Main Authors: Guiying Cao, Jue Liu, Min Liu, Jing Ni
Format: Article
Language:English
Published: Wolters Kluwer 2022-09-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000002331
_version_ 1797978573839007744
author Guiying Cao
Jue Liu
Min Liu
Jing Ni
author_facet Guiying Cao
Jue Liu
Min Liu
Jing Ni
author_sort Guiying Cao
collection DOAJ
description Abstract. Background:. Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease. China has the world's largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organization (WHO) of eliminating hepatitis B virus (HBV) as a global health threat by 2030. This study aimed to analyze data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to determine the trends in mortality of liver disease due to hepatitis B in China between 1990 and 2019 and the gap with the WHO's goal. Methods:. Annual deaths and age-standardized mortality rates (ASMRs) of liver disease due to hepatitis B in China between 1990 and 2019 were collected from GBD 2019. We calculated the percentage changes in deaths and estimated annual percentage changes (EAPCs) of ASMRs of liver disease due to hepatitis B. Results:. In China, deaths of total liver disease due to hepatitis B decreased by 29.13% from 229 thousand in 2016 to 162 thousand in 2019, and ASMR decreased by an average of 4.92% (95% confidence interval [CI]: 4.45–5.39%) per year in this period. For the spectrum of liver disease due to hepatitis B, deaths decreased by 74.83%, 34.71%, and 23.34% for acute hepatitis, cirrhosis and other chronic liver diseases, and liver cancer from 1990 to 2019, respectively, and ASMRs of acute hepatitis (EAPC = –7.63; 95% CI: –8.25, –7.00), cirrhosis and other chronic liver diseases (EAPC = –4.15; 95% CI: –4.66, –3.65), and liver cancer (EAPC = –5.17; 95% CI: –6.00, –4.33) decreased between 1990 and 2019. The proportions of older adults aged ≥70 years among all deaths of the spectrum of liver disease due to hepatitis B increased from 1990 to 2019. Deaths of liver cancer due to hepatitis B increased by 7.05% from 2015 to 2019. Conclusions:. Although a favorable trend in the mortality of liver disease due to hepatitis B was observed between 1990 and 2019, China still faces challenges in achieving the WHO's goal of eliminating HBV as a public threat by 2030. Therefore, efforts to increase the coverage of diagnosis and treatment of liver disease due to hepatitis B, especially of liver cancer due to hepatitis B, are warranted in China.
first_indexed 2024-04-11T05:25:07Z
format Article
id doaj.art-a2225e2099244631a70a8a494c194ef5
institution Directory Open Access Journal
issn 0366-6999
2542-5641
language English
last_indexed 2024-04-11T05:25:07Z
publishDate 2022-09-01
publisher Wolters Kluwer
record_format Article
series Chinese Medical Journal
spelling doaj.art-a2225e2099244631a70a8a494c194ef52022-12-23T07:54:57ZengWolters KluwerChinese Medical Journal0366-69992542-56412022-09-01135172049205510.1097/CM9.0000000000002331202209050-00005Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease StudyGuiying Cao0Jue Liu1Min Liu2Jing Ni3Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.Abstract. Background:. Hepatitis B is a viral infection that attacks the liver and can cause both potentially life-threatening acute and chronic liver disease. China has the world's largest burden of hepatitis B and is considered to be a major contributor toward the goal of World Health Organization (WHO) of eliminating hepatitis B virus (HBV) as a global health threat by 2030. This study aimed to analyze data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to determine the trends in mortality of liver disease due to hepatitis B in China between 1990 and 2019 and the gap with the WHO's goal. Methods:. Annual deaths and age-standardized mortality rates (ASMRs) of liver disease due to hepatitis B in China between 1990 and 2019 were collected from GBD 2019. We calculated the percentage changes in deaths and estimated annual percentage changes (EAPCs) of ASMRs of liver disease due to hepatitis B. Results:. In China, deaths of total liver disease due to hepatitis B decreased by 29.13% from 229 thousand in 2016 to 162 thousand in 2019, and ASMR decreased by an average of 4.92% (95% confidence interval [CI]: 4.45–5.39%) per year in this period. For the spectrum of liver disease due to hepatitis B, deaths decreased by 74.83%, 34.71%, and 23.34% for acute hepatitis, cirrhosis and other chronic liver diseases, and liver cancer from 1990 to 2019, respectively, and ASMRs of acute hepatitis (EAPC = –7.63; 95% CI: –8.25, –7.00), cirrhosis and other chronic liver diseases (EAPC = –4.15; 95% CI: –4.66, –3.65), and liver cancer (EAPC = –5.17; 95% CI: –6.00, –4.33) decreased between 1990 and 2019. The proportions of older adults aged ≥70 years among all deaths of the spectrum of liver disease due to hepatitis B increased from 1990 to 2019. Deaths of liver cancer due to hepatitis B increased by 7.05% from 2015 to 2019. Conclusions:. Although a favorable trend in the mortality of liver disease due to hepatitis B was observed between 1990 and 2019, China still faces challenges in achieving the WHO's goal of eliminating HBV as a public threat by 2030. Therefore, efforts to increase the coverage of diagnosis and treatment of liver disease due to hepatitis B, especially of liver cancer due to hepatitis B, are warranted in China.http://journals.lww.com/10.1097/CM9.0000000000002331
spellingShingle Guiying Cao
Jue Liu
Min Liu
Jing Ni
Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
Chinese Medical Journal
title Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
title_full Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
title_fullStr Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
title_full_unstemmed Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
title_short Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study
title_sort trends in mortality of liver disease due to hepatitis b in china from 1990 to 2019 findings from the global burden of disease study
url http://journals.lww.com/10.1097/CM9.0000000000002331
work_keys_str_mv AT guiyingcao trendsinmortalityofliverdiseaseduetohepatitisbinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT jueliu trendsinmortalityofliverdiseaseduetohepatitisbinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT minliu trendsinmortalityofliverdiseaseduetohepatitisbinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy
AT jingni trendsinmortalityofliverdiseaseduetohepatitisbinchinafrom1990to2019findingsfromtheglobalburdenofdiseasestudy